Abstract: Impairment of serotonin receptor and transporter function is increasingly recognized to play a major role in the pathophysiology of neuropsychiatric diseases including anxiety disorder (AD), major depressive disorder (MDD), bipolar disorder (BD) and schizophrenia (SZ). We conducted a PubMed search, which provided a total of 136 in vivo studies with PET and SPECT, in which 5-HT synthesis, 5-HT transporter binding, 5-HT 1 receptor binding or 5-HT 2 receptor binding in patients with the primary diagnosis of acute AD, MDD, BD or SZ was compared to healthy individuals. A retrospective analysis revealed that AD, MDD, BD and SZ differed as to affected brain region(s), affected synaptic constituent(s) and extent as well as direction of dysfunction in terms of either sensitization or desensitization of transporter and receptor binding sites.
Introduction
In Europe, anxiety disorder (AD) is the most frequent affective disorder with a 1-year prevalence of 12%. The prevalence of major depressive disorder (MDD) and psychotic disorders including schizophrenia (SZ) amounts to 8% and 3%, respectively (Wittchen and Jacobi, 2005) . Despite these incidences and their socioeconomic impact, pathophysiological mechanisms of psychiatric disorders are still not fully understood.
Among the neurotransmitters implicated in AD, MDD and SZ are catecholamines (AD, Stein et al., 2002; MDD, Willner, 1983; SZ, Seeman and Lee, 1975) , glutamate (AD, Carlsson, 2001; MDD, Mitchell and Baker, 2010 ; SZ, Konradi and Heckers, 2003) , acetylcholine (AD, Graef et al., 2011; MDD, Mineur and Picciotto, 2010; SZ, Hajós and Rogers, 2010) and γ-aminobutyric acid ([GABA] ; AD, Nuss, 2015; MDD, Pehrson and Sanchez, 2015; SZ, Taylor and Tso, 2014) .
A major role has also been ascribed to dysfunctions of the serotonin (5-HT)ergic system (AD, Lowry et al., 2005; MDD, Di Giovanni et al., 2006; SZ, Di Pietro and Seamans, 2007) . 5-HTergic neurons arise in mesencephalic/pontine regions (MB) including dorsal, median and rostral raphe nucleus, caudal linear nucleus, interpeduncular nucleus, B9 5-HTergic cell group and reticular formation and project to virtually every part of the brain including prefrontal (PFC), frontal (FC), parietal (PC) and occipital cortex (OC), cingulate (CING), septum, hippocampus (HIPP), parahippocampal gyrus (PHG), amygdala (AMYG), entorhinal cortex (EC), neostriatum (STR), ventral striatum (VS), substantia nigra, ventral tegmental area, thalamus (THAL), hypothalamus (HT), locus caeruleus and tuberomammillary nucleus (for review, see Hale and Lowry, 2011) .
In recent surveys of all in vivo imaging studies, which, so far, had been conducted on 5-HTergic neurotransmission in acute AD, MDD, bipolar disorder (BD) and SZ (Nikolaus et al., 2010 (Nikolaus et al., , 2012 (Nikolaus et al., , 2014a , we found (1) a significant reduction of SERT in the MB of patients with AD relative to controls; (2) significant reductions of SERT in THAL and MB and a significant elevation of SERT in the insula (INS) of patients with MDD relative to controls; (3) significant elevations of SERT in CING and INS of depressed patients with BD relative to controls; (4) significant reductions of 5-HT 1A receptors (5-HT 1 R) in MB and CING of patients with AD relative to controls; (5) a significant reduction of 5-HT 1 R in the MB of patients with MDD relative to controls; (6) significant reductions of 5-HT 1 R in MB and temporal cortex (TC) of patients with SZ relative to controls; (7) significant reductions of 5-HT 2A receptors (5-HT 2 R) in prefrontal (PFC), frontal (FC), occipital cortex (OC) and CING of patients with MDD relative to controls; and (8) significant reductions of 5-HT 2 R in FC and TC of patients with SZ relative to controls.
In these surveys, however, AD, MDD, BD and SZ had been considered separately, and no comparison of regional SERT, 5-HT 1 R and 5-HT 2 R binding had been performed between disorders. Thus, for the present study, a new PubMed search was conducted in order to update the pool of investigations. Since the number of available publications on SERT, 5-HT 1 R and 5-HT 2 R binding in AD, MDD, BD and SZ had increased by a total of 27 investigations (AD: SERT, n = 4, 5-HT 1 R, n = 1; 5-HT 2 R, n = 2; MDD: SERT, n = 10, 5-HT 1 R, n = 3, 5-HT 2 R, n = 3; BD: 5-HT 1 R, n = 2; SZ: SERT, n = 1, 5-HT 2 R, n = 1), a novel analysis was performed comparing (A) regional 5_HT synthesis as well as SERT, 5-HT 1 R and 5-HT 2 R binding separately in patients with AD, MDD, BD (depressive state [BD dep ], manic state [BD man ]) and SZ relative to healthy controls; and (B) regional SERT, 5-HT 1 R and 5-HT 2 R binding between patients with AD, MDD, BD dep , BD man and SZ.
Method Selection of studies
A PubMed search was performed using the keywords 'anxiety disorder', 'depression', 'bipolar disorder', 'schizophrenia', 'schizoaffective disorder' and 'schizophreniform disorder' in combination with either 'SERT', '5-HT 1 receptor', '5-HT 2 receptor' or '5-HT synthesis' and either 'PET' or 'SPE(C)T'.
The search provided a total of 25 investigations on acute AD [277 patients, age: 36±10 years (mean±standard deviation), duration of disease: 13±6 years, Yale-Brown Obsessive-Compulsive score (Ybocs): 24±5; Hamilton Anxiety (HAMA) Rating Scale score: 17±9; 360 controls, age: 36±10 years], 74 investigations on acute MDD [1295 patients, age: 38±8 years, duration of disease: 10±7 years, Hamilton Depression Rating Scale (HDRS) score: 24±6; 1375 controls, age: 36±10 years], 12 investigations on acute BD [BD dep , n = 10; BD man , n = 2, 174 patients, age: 34±6 years, duration of disease: 14±8 years, HDRS score: 20±6; Young Mania Rating Scale (YMRS) score: 11±9; 211 controls, age: 33±3 years] and 25 investigations on acute SZ [345 patients, age: 25±10 years, duration of disease: 5±3 years, Positive and Negative Syndrome Scale (PANSS) score: 62±12; 286 controls, age: 28±10 years] published in peer-reviewed journals between 1991 and January 2015, in which patients with the primary diagnosis of AD [obsessive-compulsive disorder (OCD), generalized anxiety disorder (GAD), panic disorder (PD), phobia], MDD, BD dep , BD man or SZ were compared to healthy individuals, and in which quantitative data were communicated (Tables 1-4) . Studies on subjects with post-traumatic stress disorder (PTSD; Bonne et al., 2005; Sullivan et al., 2013) were not included in this analysis, because -in contrast to endogenous AD such as OCD, PD, GAD or phobia -patients with PTSD per definition are exposed to a single or long-term extrinsic trauma (see the Discussion section). Rating scale scores, employed radioligand, comorbidities, smoking habits, medication prior to the investigation, disease duration, medication state at the time of the in vivo investigation and withdrawal times are listed in Tables 1-4, if specified in the individual scientific reports.
Our analysis included all available in vivo investigations on patients with AD, MDD, BD dep , BD man and SZ in the acute stage of disease irrespective of the medication state (Tables 1-4 ). Data were evaluated as previously described (Nikolaus et al., 2010 (Nikolaus et al., , 2012 (Nikolaus et al., , 2014a . Percentual differences of SERT binding, 5-HT 1 R binding, 5-HT 2 R binding or 5-HT synthesis to the respective control groups of healthy individuals were computed for the following brain regions: STR (nucleus caudate, putamen), VS, globus pallidus (GP), THAL, HT, PFC (Brodmann areas 9-12, 46, 47 and 49), FC (PFC plus Brodmann areas 4 and 6), PC (Broadmann areas 3, 5, 7, 8, 39 and 40) , TC (Brodmann areas 20-22, 38, 41 and 42) , OC (Brodmann areas 17-19), CING, HIPP, PHG, AMYG, INS, EC, fusiform gyrus (FG), periaqueductal gray (PAG), MB (midbrain, pons) and cerebellum (CER). Left and right radioactivity accumulations were pooled if given separately in the original publication. If the authors had analyzed more than one area within STR, PFC, FC, PC, TC, OC and CING, the mean values of these data were computed for patients with AD, MDD, BD dep , BD man and SZ and the respective controls before calculating percentual differences.
Statistic calculations were performed using IBM SPSS Statistics 22 (IBM Germany, Ehningen, Germany). In the majority of cases, the Kolmogorov-Smirnov test for the normal distribution could not be performed, since the sum of weighted cases per disorder and brain region fell short of 5. Therefore, medians of percentual differences of SERT binding, 5-HT 1 R binding, 5-HT 2 R binding or 5-HT synthesis in the individual brain regions relative to controls were computed for patients with AD, MDD, BD dep , BD man and SZ. Differences between patients with AD, MDD, BD dep , BD man and SZ and the respective controls were assessed with the non-parametric Wilcoxon signed-rank test (α = 0.05) for paired samples. Differences between the individual disorders (AD vs Given are the reference (in alphabetical order), the assessed disorder, mean rating scale scores (±SD), employed radioligands comorbidities, premedication, cigarette smoking habits, numbers of (male and female) patients and controls, mean age of patients and controls (±SD; years), mean duration of disease (±SD; years), medication state at the time of the investigation and duration of withdrawal (days Given are the reference (in alphabetical order), the assessed disorder, mean rating scale scores (±SD), employed radioligands comorbidities, premedication, cigarette smoking habits, numbers of (male and female) patients and controls, mean age of patients and controls (±SD; years), mean duration of disease (±SD; years), medication state at the time of the investigation and duration of withdrawal (days). AD, anxiety disorder; ADHD, attention-deficit hyperactivity disorder; BD, bipolar disorder; BDI, Beck Depression Inventory; BED, binge eating disorder; BPD, borderline personality disorder; BSIC, Beck Suicidal Intent Scale; CD, conduct disorder; CGIS, Clinical Global Impression Scale; D vs. BD man ) were assessed with the non-parametric MannWhitney U-test (α = 0.05) for unrelated samples. No corrections were made for multiple comparisons. As implied by the outcome of our previous surveys on AD, MDD and SZ (Nikolaus et al., 2009 (Nikolaus et al., , 2010 (Nikolaus et al., , 2012 (Nikolaus et al., , 2014a , significance tests were performed one-sidedly.
Results
Comparison between patients and controls 
BD dep
Significant elevations of SERT ( Figure 1) Given are the references (in alphabetical order), the assessed disorder, mean rating scale scores (±SD), employed radioligands, comorbidities, premedication, cigarette smoking habits, numbers of (male and female) patients and controls, mean age of patients and controls (±SD; years), mean duration of disease (±SD; years), medication state at the time of the investigation and duration of withdrawal (days 
Comparison between disorders SERT
SERT ( Figure 1 ) was reduced in the TC (-14%, p, 0.076) of patients with AD compared to patients with MDD; the difference, however, marginally failed to reach statistical significance. Further decrements were observed in the THAL (-28%, p, 0.078) of patients with AD compared to patients with BD dep and in the MB (-31%, p, 0.074) of patients with AD compared to patients with BD man , which also did not reach statistical significance. There was neither a significant difference of SERT binding between AD and SZ, nor between MDD and SZ and SZ and BD man . Given are the reference (in alphabetical order), the assessed disorder, mean rating scale scores (±SD), employed radioligand(s), comorbidities, premedication, cigarette smoking habits, numbers of (male and female) patients and controls, mean age of patients and controls (±SD; years), mean duration of disease (±SD; years), medication state at the time of the investigation and duration of withdrawal (days 
5-HT 1 R

Discussion
Summary of findings SERT
The most extensive decline of SERT relative to controls was observed in MDD involving both neocortical (PFC) and subcortical regions (MB, STR, THAL, AMYG). In AD, SERT decline relative to controls was confined to MB, THAL and AMYG, whereas no decline of SERT binding was observed in SZ. Moreover, in contrast to AD and SZ, increases of SERT relative to healthy individuals were detected in the INS of patients with MDD and in CING and INS of patients with BD dep , while investigations on BD man yielded evidence of increased mesencephalic SERT. A comparison between disorders yielded no significant differences of SERT binding. However, there was a trend towards a reduction of SERT in the TC of patients with AD compared to those with MDD, in the THAL of patients with AD compared to those with BD dep , in the MB of patients with AD compared to those with BD man , and in THAL and HIPP of patients with MDD compared to those with SZ. 
5-HT 1 R
The most extensive decline of 5-HT 1 R relative to controls was observed in AD involving neocortex (FC), CING, MB and various limbic regions (HIPP AMYG, INS). In SZ, decreases of 5-HT 1 R relative to controls were observed in the MB. In contrast to AD, however, 5-HT 1 R were reduced in TC and OC, but not in the FC. Limbic reductions, moreover, were less extensive, merely affecting the AMYG. Similar to AD and SZ, mesencephalic 5-HT 1 R were lowered in MDD relative to controls. In contrast to AD and SZ, however, no reductions of limbic 5-HT 1 R were detected. Rather, 5-HT 1 R were found to be elevated in the PHG relative to controls. HIPP of patients with MDD compared to those with BD dep and in the AMYG of patients with SZ compared to those with BD dep .
5-HT 2 R
The most extensive decline of 5-HT 2 R relative to controls was found in BD man involving the whole neocortex (FC, PC, TC, OC) as well as CING, INS and FG. Evidence, however, is limited, since findings were obtained in merely one study. In SZ, 5-HT 2 R reductions relative to normal subjects were confined to the neocortex (FC, TC, OC), while in MDD, no reductions were detected in the TC. In contrast to SZ, however, 5-HT 2 R, additionally, were diminished in PFC and CING. Contrary to MDD, BD man and SZ, an elevation of temporal 5-HT 2 R relative to controls was observed in AD.
No investigations of 5-HT 2 R were available on BD dep . A comparison between disorders revealed increases of 5-HT 2 R in the TC of patients with AD compared to those with MDD, in the FC and TC of patients with AD compared to those with SZ and in the FC of patients with MDD compared to those with SZ. Moreover, there was a trend towards the elevation of 5-HT 2 R in the CING of patients with AD compared to those with MDD and in the OC of patients with AD compared to those with SZ. , and schizophrenia (SZ). Considered were 3 studies on AD (33 patients, age: 34±4 years; 39 controls, age: 35±5 years), 19 studies on MDD (287 patients, age: 39±9 years; 279 controls, age: 37±10 years), 1 study on BD man (10 patients, age: 34±12 years; 10 controls, age: 34±6 years), and 14 studies on SZ (199 patients, age: 30±4 years; 216 controls, age: 28±3 years), in which 5-HT 2 R were assessed in neostriatum (STR), globus pallidus (GP), prefrontal cortex (PFC), frontal cortex (FC), parietal cortex (PC), temporal cortex (TC), occipital cortex (OC), cingulate (CING), hippocampus (HIPP), amygdala (AMYG), insula (INS), parahippocampal gyrus (PHG), fusiform gyrus (FG), midbrain/pons (MB) and cerebellum (CER). The box plots give medians, 25-/75-percentiles and 5-/95-percentiles of the individual synaptic constituents in the investigated brain regions expressed as percentages of control values. The circles represent the percentages of control values in the individual investigations (white circles, percentual difference relative to controls not significant in the original investigation; black circles, percentual difference relative to controls significant in the original investigation with a p of at least 0.05). Asterisks indicate significant differences of the pooled samples of AD, MDD, BD man or SZ patients relative to the pooled samples of controls (Wilcoxon signed-rank test, one-sided, α = 0.05) and significant differences between pooled samples of AD, MDD, BD man or SZ (Mann-Whitney U-test, one-sided, α = 0.05).
5-HT synthesis
5-HT synthesis was merely assessed in patients with MDD.
No alterations were detected relative to healthy controls. (Nikolaus et al., 2010 (Nikolaus et al., , 2014b .
Role of 5-HT in neuropsychiatric disorders
If we proceed from the assumption that regulatory mechanisms aim to maintain functional homeostasis throughout the central nervous system (Andrews et al., 2011) , we may tentatively surmise the following interactions between 5-HT, DA and GABA in acute AD: first, DA is known to inhibit the release of GABA via D 2 R action (Girault et al., 1986) . Consequently, the observed desensitization of inhibitory striatal D 2 R may lead to an increase of available GABA in the STR as well as in the projection areas of striatothalamocortical GABAergic neurons; this is consistent with the detected decreases of striatal, neocortical and limbic GABA A R in AD.
Secondly, GABA exerts inhibitory effects on both DA (Grace and Bunney, 1979 ) and 5-HT neurons (Luparini et al., 2004) . The desensitization of GABA A R in STR, FC, TC, OC, CING, AMYG and INS, thus, will diminish the inhibitory GABAergic input to DA and 5-HT neurons leading to an elevation of both DA and 5-HT concentrations throughout the mesolimbocortical system.
The desensitization of (inhibitory) D 2 heteroreceptors in striatal tissues of AD may be interpreted as an adaptive response to the increase of available DA. Likewise, the desensitization of 5-HT 1 heteroreceptors in MB, FC, CING, HIPP, AMYG and INS can be conceived to compensate for the increase of 5-HT concentrations. Since 5-HT acts to facilitate DA release via several subtypes including 5-HT 1A R, 5-HT 1B R, 5-HT 2A R, 5-HT 3 R and 5-HT 4 R (for review, see Alex and Pehek, 2007) , the 5-HT 1 R desensitization in MB, FC, CING, HIPP, AMYG and INS is likely to elicit an adaptive decline of DA efflux in these regions. Moreover, the decrease of available inhibitory D 2 in the STR and of 5-HT 1 autoreceptors in FC, CING, HIPP, AMYG and INS can be presumed to entail a reduction of feedback inhibition resulting in a further enhancement of striatal DA and midbrain, frontal, cingulate and limbic 5-HT release, which is likely to fuel DAergic neurotransmission in the target regions of ascending DAergic striatothalamocortical fibers as well as 5-HTergic neurotransmission in both ascending and descending fibers of the mesolimbocortical system. Conversely, the decrease of (inhibitory) D 2 and 5-HT 1 heteroreceptors may be assumed to counterbalance the increase of DAergic/5-HTergic activity by reducing the inhibitory actions exerted by these binding sites. This is likely to result in a net overweight of excitatory input to the target regions of DAergic and 5-HTergic projections.
Taken together, 5-HTergic function in acute AD may be characterized by an abundance of 5-HT and a net overweight of excitatory input (due to the desensitization of inhibitory 5-HT 1 R binding sites) to the target regions of ascending and descending 5-HTergic projections. This is consistent with the 5-HT hypothesis of AD proposing increased 5-HTergic activity (for review, see Lowry et al., 2005) . In particular, the Deakin/Graeff theory (Deakin and Graeff, 1991) surmises different pathways controlling behavioral responses to aversive stimuli. Thereby, the dorsal raphe periventricular tract is supposed to inhibit 'fight-or-flight' responses by stimulation of 5-HT 1A R and/ or 5-HT 2A R. Disinhibition of this pathway is believed to result in bouts of sympathetic and behavioral arousal comparable to PD (for review, see Paul and Lowry, 2013) . The mesencephalic 5-HT 1 R desensitization observed in the present analysis and the resulting disinhibition, thus, are in line with the hypothesized 5-HT 1A R dysfunction in the dorsal raphe periventricular tract. Moreover, according to the Deakin/Graeff hypothesis, risk assessment and avoidance behaviors are facilitated by the dorsal raphe forebrain bundle tract via activation of the 5-HT 2A/2C R and 5-HT 3 R binding sites, which is in agreement with the net overweight of excitatory input to the neocortical and limbic target regions of mesencephalic efferents.
In the present analysis, SERT binding was found to be decreased in MB, THAL and AMYG. This implies that SERT dysfunction in these regions at least may add to the increased availability of 5-HT caused by the desensitization of the D 2 R and GABA A R binding sites. Moreover, 5-HT 2 R binding was unaltered throughout most part of the neocortex with a significant elevation in the TC. Although the latter finding must be viewed with caution, since it was obtained on a pool of merely two studies, it may not be dismissed that sensitization/desensitization mechanisms of 5-HT 2 R binding sites are basically disturbed impeding adaptation to altered neocortical 5-HT levels. This possibility is underlined by the results of several experiments indicating an association between HTR2A gene variants and psychiatric disorders including AD (for review, see Serretti et al., 2007) .
As follows from Table 1 , all but one study had been conducted on patients who were drug-free at the time of scanning. Withdrawal times had not always been specified; according to the reports in which they had been given, they lay between 8 and 168 days. Thus, the effect of precedent anxiolytic treatment on the outcome of the present analysis is difficult to gauge. Further in vivo investigations are needed, in which SERT, 5-HT 1 R and/or 5-HT 2 R binding are measured before, under and after acute medication with anxiolytic compounds in order to assess the effect of treatment(s) on receptor/transporter regulation states and to relate it to the acute or remitted stage of the disease.
MDD and BD
Patients with MDD displayed significant reductions of SERT in STR, THAL, PFC, MB and AMYG, a significant elevation of SERT in the INS, a significant reduction of 5-HT 1 R in the MB, a significant elevation of 5-HT 1 R in the PHG and significant reductions of 5-HT 2 R in CING, PFC, FC and OC. Previous analyses had revealed no alterations of DA and GABA receptor binding sites in any of the investigated brain regions but an increase of DA synthesis in the FC (Nikolaus et al., 2012 (Nikolaus et al., , 2014b . Patients with BD dep showed significant increases of cingulate and insular SERT as well as hippocampal, amygdalar and parahippocampal 5-HT 1 R binding sites, whereas in patients with BD man , 5-HT 2 R were significantly diminished in FC, PC, TC, OC, CING, INS and FG. Previous analysis of both BD dep and BD man , in addition, had shown a trend towards elevated striatal D 2 R and reduced frontal D 1 R binding (Nikolaus et al., 2012) . GABA A R binding has so far neither been assessed in patients with BD dep nor in those with BD man .
In the present study, 5-HT synthesis did not differ between patients with MDD and healthy controls. Moreover, since no impairment of D 2 R or GABA A R function was detected, no elevation of 5-HT release due to D 2 R and GABA A R desensitization can be inferred. Still, however, SERT binding was reduced in MB as well as STR, THAL, PFC and AMYG of patients with MDD. Given the known association between MDD and variations of the SERT gene SLC6A4 (for review, see Serretti and Mandelli, 2008) , it is not unlikely that SERT hypofunction constitutes the initial deficit in MDD leading to an abundance of 5-HT throughout the mesolimbocortical system. First, the observed desensitization of mesencephalic 5-HT 1 heteroreceptors may be conceived to compensate for the increase of 5-HT levels by reducing inhibitory neurotransmission, which -as in AD -is likely to result in a net overweight of excitatory input to the target regions of ascending 5-HTergic projections. Secondly -as in AD -the desensitization of mesencephalic 5-HT 1 autoreceptors can be assumed to lead to a reduction of feedback inhibition resulting in an enhancement of 5-HT release and a further elevation of mesencephalic 5-HT levels. In contrast to AD, however, the resulting net overweight of excitatory 5-HTergic input to the neocortical and cingulate projection areas causes an adaptive desensitization of 5-HT 2 R in PFC, FC, OC and CING leading to a compensatory reduction of excitatory neocortical and cingulate neurotransmission.
As mentioned above, 5-HT stimulates DA release via several subtypes including the 5-HT 2A R (for review, see Alex and Pehek, 2007) . Since 5-HT 2 R are desensitized in PFC, FC, OC and CING, it may be concluded that DA efflux is diminished in these regions in acutely depressed patients. Given the higher expression of D 1 R relative to D 2 R in neocortical tissues (Palacios et al., 1988) , the reduction of available DA can be inferred to induce a net reduction of excitatory action in the descending corticothalamostriatal fibers, which may be conceived to reflect an additional adaptation to the elevation of excitatory neurotransmission.
Our previous analysis of in vivo imaging studies on patients with BD dep had revealed an elevation of striatal D 2 R as well as a reduction of frontal D 1 R binding sites. Moreover, muscarinic M2R were found to be diminished in PFC, FC, OC as well as CING (Nikolaus et al., 2012) . DA inhibits 5-HT efflux via the D 2 R binding site (Ferré et al., 1994) , whereas acetylcholine facilitates 5-HT release via both muscarinic and nicotinic receptors (Marchi et al., 1988) . Thus, it may be concluded that the striatal increase of D 2 R and the neocortical and cingulate decrease of M2R jointly act to decrease 5-HT concentrations throughout the mesolimbocortical system.
In the CING and INS of patients with BD dep , SERT binding was elevated relative to controls, which, for one, may be interpreted in terms of the increased availability of 5-HT in these regions. If this be the case, the reduction of 5-HT efflux effected by the decrease of the D 2 R and M2R binding sites would reflect an adaptive mechanism compensating for the abundance of 5-HT. This is unlikely, however, since the sensitization of hippocampal, amygdalar and parahippocampal 5-HT 1 auto-and hetereoreceptors, rather, indicates a shortage of available 5-HT. The sensitization of limbic 5-HT 1 heteroreceptors, for one, may be conceived to counteract this shortage by increasing inhibitory neurotransmission, which is likely to result in a net reduction of excitatory input to the target regions of ascending and descending 5-HTergic fibers. Secondly, however, the sensitization of limbic 5-HT 1 autoreceptors may enhance feedback inhibition entailing a reduction of 5-HT release and a further decline of limbic 5-HT levels. As a matter of fact, this effect is likely to be aggravated in the INS by the observed elevation of SERT binding sites. Since 5-HT action stimulates DA release, and 5-HT 1 R binding sites are sensitized in HIPP, AMYG and PHG, it, furthermore, may be surmised that DA efflux is increased in these regions leading to an augmentation of DAergic activity in ascending limbocortical fibers. This conjecture is supported by the desensitization of D 1 R in the FC of patients with BD dep .
Strikingly, in MDD, the desensitization of mesencephalic 5-HT 1A auto-and heteroreceptors was accompanied by a sensitization of parahippocampal 5-HT 1 R binding sites. This corresponds to the increase of 5-HT 1 R, which was observed in the limbic system of patients with BD dep . Thus, the same line of events -sensitization of parahippocampal 5-HT 1 heteroreceptors leading to an increase of inhibitory input and sensitization of parahippocampal 5-HT 1 autoreceptors leading to a decline of 5-HT levelsalso may be assumed to take place in MDD. Altogether, this implies an interaction of limbic and mesencephalic 5-HT function in MDD, which is not present in BD dep . Thereby, it can be hypothesized that, in MDD, the net excitatory influence of 5-HTergic projections ascending from the MB to limbic and neocortical target regions counterbalances the inhibitory influence of 5-HTergic fibers projecting from the limbic system to the neocortex. Thereby, it remains inconclusive, to which degree the net excitation exerted by the MB on the neocortex counteracts the inhibition exerted by the limbic system, and to which degree the excitatory effects exerted by the MB on the limbic system, rather, enhance the inhibitory actions of the limbocortical efferents. Possibly, the mesencephalic-limbic loop even acts in conjunction with the desensitization of neocortical 5-HT 2 R binding sites resulting in a net inhibition of the neocortex.
In contrast to BD dep , where mesencephalic SERT binding was unaffected, patients with BD man displayed an increase of SERT in this region. Although this finding must be viewed with caution, since it was obtained in merely one investigation, it may be tentatively interpreted in terms of an increased availability of 5-HT in the MB resulting in an augmentation of 5-HTergic activity in the neocortical and limbic target regions of 5-HTergic efferents. This is also reflected by the (compensatory) desensitization of 5-HT 2 R in both neocortical and limbic areas. Unfortunately, no in vivo investigations have been conducted, so far, on 5-HT 1 R binding in BD man , while in BD dep no investigations are available on 5-HT 2 R. Thus, at present, it may only be hypothesized that mesencephalic and neocortical 5-HT levels are increased in BD man , whereas BD dep is characterized by a shortage of limbic 5-HT.
As mentioned above, a previous analysis of BD man had revealed a trend towards elevated striatal D 2 R and reduced frontal D 1 R binding sites (Nikolaus et al., 2012) . Since 5-HT stimulates DA release, and 5-HT 2 R binding sites are desensitized in neocortex, CING and limbic regions, it may be surmised that DA efflux is decreased in these areas and in the target regions of corticothalamostriatal projections. This conjecture is supported by the sensitization of D 2 R in the STR but not by the desensitization of D 1 R in the FC of patients with BD man . Since, however, findings on D 1 R and D 2 R binding were obtained in merely three studies (D 1 R: n = 1, D 2 R: n = 2), future investigations are needed to shed further light on this matter.
Taken together, it may be hypothesized that acute MDD and BD man are associated with abundance of 5-HT, whereas BD dep may be characterized by a shortage of this neurotransmitter. In MDD, the net overweight of excitatory 5-HTergic input (due to the desensitization of mesencephalic 5-HT 1 R) -in contrast to AD -is compensated by a desensitization of 5-HT 2 R binding sites in the target regions of ascending 5-HTergic projections. This also holds for BD man , with the constraint that, presently, information on the regulation state of HT 1 R is lacking. In BD dep , the sensitization of limbic 5-HT 1 heteroreceptors counteracts the decrease of available 5-HT by increasing inhibitory neurotransmission, which is likely to result in a net reduction of excitatory input to the target regions of ascending and descending 5-HTergic projections. Moreover, in both MDD and BD dep , limbic 5-HT 1 R are sensitized, which may be hypothesized to enhance the inhibitory action of limbocortical efferents. In MDD, however, the inhibitory actions exerted by the limbic system may be balanced by net excitatory influence from the MB.
The 5-HT hypothesis of MDD proceeds from the notion of reduced activity in the 5-HTergic system (for review, see Di Giovanni et al., 2006) and is supported by the antidepressant effects of selective 5-HT reuptake inhibitors (SSRIs) and 5-HT 1A R agonists (for review, see Stein et al., 2002; Savitz et al., 2009) . At first glance, the outcome of the present analysis does not seem to agree with this hypothesis, since the observed desensitizations of both mesencephalic 5-HT 1 R and neocortical and cingulate 5-HT 2 R binding sites, rather, reflect an increased availability of 5-HT. On the other hand, 5-HT 1A R sensitization in the PHG of patients with MDD and in the HIPP, AMYG and PHG of the patients with BD dep argues in favor of lowered 5-HT levels in the limbic system. Conversely, the reduction of SERT in the MB, STR, THAL, PFC of patients with MDD supports the 5-HT hypothesis, which, however, does not hold for the increased amount of SERT in the CING and INS of subjects with BD dep .
As follows from Tables 2 and 3 , the majority of studies on MDD and BD had been conducted on patients who were drug-free at the time of scanning. However, in a total of 17 studies on MDD and in a total of 4 studies on BD, the medication state had either not been specified, or the investigations had been conducted entirely or partly on acutely medicated subjects. In the studies on drug-free individuals, withdrawal times had not always been specified; according to those reports in which they had been given, they lay between 3 days and 5 years. Thus, the effect of precedent antidepressant treatment on the outcome of the present analysis is difficult to gauge. Antidepressants act by a variety of mechanisms including 5-HT and noradrenaline (NA) reuptake inhibition, 5-HTR antagonism, α 2 adrenoreceptor antagonism and GABA A R agonism. As a consequence, a variety of actions are conceivable. Without prejudice to the 5-HT hypothesis, the abundance of 5-HT implied by the present analysis, for instance, may -partially or wholly -be due to treatment with tricyclics, SSRIs and 5-HT/NA reuptake inhibitors (SNRIs). 5-HT 1 R and 5-HT 2 R antagonist treatment, on the other hand, at least may have contributed to the observed decrease of available 5-HTR binding sites, while GABA A R agonistic benzodiazepines may have counteracted 5-HT affluence by inhibiting 5-HT release. It is interesting, however, that -notwithstanding the likely effects of tricyclics, SSRIs and SNRIs in augmenting synaptic 5-HT levels -SERT binding was found to be reduced. This may be accounted for either by the fact that the majority of studies had not been conducted on acutely medicated patients, or by a basic dysfunction of SERT regulation. Taken together, also in MDD and BD, further in vivo investigations are needed, in which SERT, 5-HT 1 R and/or 5-HT 2 R binding are determined before, under and after acute medication in order to assess the effect of treatment(s) on the regulation states of binding sites and to relate it to the acute or remitted stage of either disease.
SZ
Patients with SZ displayed significant reductions of 5-HT 1 R in TC, OC, MB and AMYG, while 5-HT 2 R were significantly lowered in FC, TC and OC. Previous findings, additionally, had evidenced significant elevations of DA synthesis and release, and significant reductions of striatal D 1 R, striatal, thalamic, frontal and parietal D 2 R, and striatal DA transporter (DAT) as well as frontal and temporal GABA A R binding (Nikolaus et al., 2014a,b) .
Since D 2 R inhibit the release of GABA (Girault et al., 1986) , D 2 R desensitization in STR, THAL, FC and TC is likely to induce a disinhibition resulting in an elevation of available GABA in both the STR and the projection areas of ascending striatothalamocortical GABAergic neurons. This conjecture is in agreement with the detected decreases of neocortical GABA A R in SZ.
Since GABA exerts inhibitory effects on both DA (Grace and Bunney, 1979 ) and 5-HT neurons (Luparini et al., 2004) , the desensitization of GABA A R in FC and TC, in turn, can be presumed to diminish the inhibitory GABAergic input to DA and 5-HT neurons leading to an elevation of both DA and 5-HT concentrations throughout the mesolimbocortical system.
The desensitization of striatal D 1 R and striatal, thalamic, frontal and parietal D 2 R may be interpreted as an adaptive response to the overall increase of available DA. Likewise, the desensitization of 5-HT 1 R in MB, TC, OC and AMYG and 5-HT 2 R in FC, TC and OC can be conceived to compensate for the augmentation of 5-HT concentrations. Moreover, since 5-HT stimulates DA release (for review, see Alex and Pehek, 2007 ) and 5-HT 1 R and 5-HT 2 R are desensitized in MB, neocortex and AMYG, DA concentrations are likely to be additionally diminished via desensitization of 5-HTR binding sites.
The decrease of available D 2 autoreceptors in STR, THAL, FC and PC and 5-HT 1 autoreceptors in STR and MB, TC, OC and AMYG can be presumed to lead to a reduction of feedback inhibition resulting in a further augmentation of DA and 5-HT release, which is likely to enhance DAergic and 5-HTergic neurotransmission in both ascending and descending fibers of the mesolimbocortical system. In turn, the decrease of D 2 and 5-HT 1 heteroreceptors may be assumed to counterbalance the increase of DAergic/5-HTergic activity by reducing the inhibitory actions exerted by these binding sites. As in AD and MDD, this is likely to result in a net overweight of excitatory input to the target regions of ascending and descending DAergic as well as 5-HTergic neurons. As in MDD, but unlike AD, the net overweight of excitatory 5-HTergic input to neocortical projection areas is compensated by a desensitization of 5-HT 2 R in FC, OC and CING leading to a reduction of excitatory input to the mesolimbic target regions of neocortical afferents. Interestingly, in AD and SZ -unlike MDD and BD dep -no elevation of limbic 5-HT 1 R was observed implying entirely different modes of limbic 5-HT action.
Taken together, acute SZ is characterized by an abundance of 5-HT, which is compensated by the desensitization of mesencephalic, limbic and neocortical 5-HT 1 R as well as neocortical 5-HT 2 R binding sites. The increased availability of 5-HT is likely to be caused by the desensitization of the D 2 R and GABA A R binding sites throughout the brain. We have previously hypothesized that SZ in unmedicated patients may be associated with an impaired mechanism of both D 2 auto-and heteroreceptor sensitization leading to sensitization instead of desensitization in response to increased levels of neostriatal DA (Nikolaus et al., 2014a,b) . The basal increase of available presynaptic D 2 autoreceptors may constitute an adaptive mechanism, which, however, remains ineffective in decreasing DA synthesis/release. Moreover, the sensitization of postsynaptic D 2 heteroreceptors enhances the inhibitory actions exerted by these binding sites. This can be hypothesized to cause a decrease of GABA efflux in the neostriatum as well as in the thalamic and neocortical target regions of GABAergic projections, ultimately resulting in a reduction of inhibitory input to the target regions of descending corticothalamostriatal efferents.
As follows form Table 4 , the majority of investigations had been conducted on acutely medicated patients. With the onset of neuroleptic treatment both excitatory and inhibitory DA and 5-HT binding sites become functionally desensitized. D 2 antagonistic medication causes a disinhibition of the (inhibitory) DA actions mediated by this receptor subtype leading to an -at least partial -restoration of inhibitory GABAergic input to the STR and to the target regions of striatothalamocortical projections. 5-HT 1A R and 5-HT 2A R antagonistic compounds block excitatory and inhibitory 5-HTergic neurotransmission (including neocortical DA release elicited via both neocortical 5-HT 1A R and 5-HT 2A R binding sites) resulting in a decrease of both 5-HTergic and DAergic excitatory input to the mesolimbic target regions of neocortical afferents.
Appraisal of results
Findings evidenced that AD, MDD, BD and SZ differed as to affected brain region(s), affected synaptic constituent(s) and extent as well as direction of dysfunction in terms of either sensitization or desensitization of transporter and receptor binding sites. The outcome of the present analysis, which included findings obtained in 27 additional investigations, complements previous results on SERT, 5-HT 1 R and 5-HT 2 R function in AD, MDD, BD and SZ (Nikolaus et al., 2009 (Nikolaus et al., , 2010 (Nikolaus et al., , 2012 (Nikolaus et al., , 2014a .
Acute AD is associated with increased 5-HT levels and a net overweight of excitatory input due to the desensitization of inhibitory mesencephalic, limbic, cingulate and frontal 5-HT 1 R. Also in acute MDD and BD man , an abundance of 5-HT can be inferred. In contrast to AD, however, the net overweight of excitatory 5-HTergic input (due to the desensitization of mesencephalic 5-HT 1 R) is compensated by a desensitization of limbic, cingulate and neocortical 5-HT 2 R. BD dep can be related to 5-HT shortage. In this condition, the sensitization of limbic 5-HT 1 heteroreceptors may be surmised to counteract the decrease of available 5-HT by increasing inhibitory neurotransmission ultimately leading to a net reduction of excitatory input to the target regions of 5-HTergic projections. Moreover, in both MDD and BD dep , limbic 5-HT 1 R are sensitized, which can be hypothesized to strengthen the inhibitory action of limbocortical efferents. In MDD -in contrast to BD dep -these inhibitory actions may be balanced by a net excitatory influence from the MB. Also in acute SZ, an abundance of 5-HT can be surmised. Since the majority of investigations on SZ were conducted on acutely medicated patients, it may be assumed, however, that mesencephalic, limbic and neocortical 5-HT 1A R as well as neocortical 5-HT 2A R were functionally desensitized resulting in a decrease of both inhibitory and excitatory input to the target regions of 5-HTergic projections.
Comparisons between disorders revealed that, in AD, frontal 5-HT 1 R were not only significantly decreased relative to healthy individuals but also relative to MDD and SZ (where they were unaltered). Moreover, in AD, frontal, cingulate, amygdalar and mesencephalic 5-HT 1 R were not only significantly lowered relative to controls but also relative to SZ -thereby, in SZ, frontal and cingulate 5-HT 1 R binding were unaltered, whereas amygdalar and cingulate 5-HT 1 R were decreased relative to controls. Additionally, in AD, temporal 5-HT 1 R were not different from healthy individuals but significantly elevated compared to patients with SZ (where they were unaltered). Conversely, in AD, temporal 5-HT 2 R were not only significantly elevated relative to healthy individuals but also relative to MDD (where they were unaltered) and to SZ (where they were decreased compared to controls). Moreover, frontal 5-HT 2 R were not only significantly elevated in AD compared to normal subjects but also relative to SZ (where they were decreased compared to controls). Additionally, in MDD, frontal 5-HT 2 R were significantly reduced relative to healthy individuals and significantly elevated relative to SZ (where they were decreased compared to controls).
From this it may be inferred that frontal and limbic 'inhibition' -as exerted via 5-HT 1 R binding sites -is lower in AD relative to MDD and SZ, whereas temporal 'inhibition' is augmented (at least relative to SZ). Furthermore, it may be conjectured that frontal and temporal 'excitation' -as exerted via 5-HT 2 R binding sites -is higher in AD relative to MDD and SZ, and higher in MDD relative to SZ (at least as much as the frontal cortex is concerned). Limbic regions such as the amygdala play a major role in the mediation of fear (for review, see Herry and Johansen, 2014) . Furthermore, prefrontal/frontal areas are involved in associative learning (for review, see Hélie et al., 2015) , while the hippocampus and medial temporal structures mediate the formation and consolidation of declarative memory (for review, see Huijgen and Samson, 2015) . Thus, it can be hypothesized that region-specific alterations of 5-HT 1 R and 5-HT 2 R may be related to specific disturbances in the processing of emotion and memory in the individual disorders. This is also likely to hold for BD dep and BD man , although the alterations observed in these conditions are difficult to position in relation of AD, MDD and SZ. With trends towards an elevation of hippocampal 5-HT 1 R in BD dep relative to MDD (where it is unaltered) and of amygdalar 5-HT 1 R relative to SZ (where it is reduced compared to controls), it may be speculated, however, that limbic 'inhibition' -as exerted via 5-HT 1 R binding sites -is elevated in BD dep relative to MDD and SZ.
Although the conjecture of region-specific alterations of 5-HT 1 R, 5-HT 2 R and SERT is intriguing, it must be put into perspective: first, investigations of some individual synaptic constituents in individual diseases are scarce with merely three studies of 5-HT 2 R in AD (Table 1) , three studies on SERT in SZ (Table 4 ) and one study, each, on SERT and 5-HT 2 R in BD man (Table 3) . Moreover, so far, no study has been conducted on 5-HT 1 R in BD man , and on 5-HT synthesis in AD, BD dep , BD man and SZ. In numerous cases, furthermore, the number of available studies per brain region is limited (Figures 1-3) . If, in addition, the number of investigated subjects is comparatively small, findings are difficult to interpret as to their portability.
Secondly, the individual findings underlying the obtained differences between patients with AD, MDD, BD dep , BD man and SZ and the respective controls were rather inconsistent with reports of no alterations and both significant and non-significant increases as well as decreases of SERT, 5-HT 1 R and 5-HT 2 R binding (Figures  1-3) . Thereby, inconclusive results may be due to varying subtypes of either disease, varying comorbidities, varying disease durations and varying disease severities, which, in addition, have been assessed with a variety of different inventories (Tables 1-4). All of these variables are likely to influence the regulation states of neurotransmitters and their receptive sites, and, therefore, may lead to results, which are incomparable not only between individual patients but also between the patient cohorts of different studies. Further factors bearing an effect on the comparability of in vivo findings are differences in methodology: results cannot be expected to be entirely consistent, when they were obtained with different imaging tools such as SPECT and the higher resolving PET, with radioligands differing as to their affinity for the respective binding sites, and -last but not least -with quantification methods ranging from the determination of simple count rates to statistical parametric mapping of distribution volumes.
Thirdly, it must be taken into account that in the majority of original investigations, patients had undergone previous and/or current treatment with anxiolytics, antidepressants and neuroleptics acting, among others, on pre-and postsynaptic DA, 5-HT, NA and GABA binding sites (Tables 1-4) . As of yet, far too little investigations are available on 5-HT function in medication-naïve patients to permit meaningful conclusions on the potential effects of pharmacological compounds within the frameworks of 5-HT 1 R, 5-HT 2 R and SERT action and their relation to other neurotransmitter systems.
In order to advance our understanding of 5-HTergic neurotransmission in neuropsychiatric disorders, future efforts must be directed towards investigating 5-HT 2 R in AD and BD dep as well as 5-HT 1 R in BD man . Moreover, it may be surmised that regional differences of SERT, 5-HT 1 R and 5-HT 2 R not only exist between disorders but also between the subtypes of AD and MDD, BD dep , BD man and SZ, and that they are related to the predominance of the respective key symptoms.
As to AD, SERT binding was nearly exclusively assessed in patients with OCD (14 studies) supplemented by 2 studies each on PD and GAD, respectively (Table 1) . Similarly, 5-HT 1 R was determined in patients with PD (3 studies) and social phobia (1 study), while 5-HT 2 R was solely investigated in patients with OCD (3 studies). In a previous paper, we have reported differences of SERT and 5-HT 1 R binding between individual subtypes of AD with reductions of SERT in MB and THAL of individuals with OCD and PD but not in patients with GAD, and reductions of 5-HT 1 R in the TC -in addition to decrements in FC and limbic regions -of individuals with PD but not in patients with phobia (Nikolaus et al., 2010) . This may indicate patterns of 5-HT (dys)function, which not only differ between AD and the other disorders, but also between the individual subtypes of AD. In this context, it is interesting that patients with PTSD -in contrast to patients with PD and phobia -display no reduction of inhibitory 5-HT 1 R binding sites in any of the assessed neocortical and subcortical regions including PFC, FC, PC, TC, OC, CING, HIPP, AMYG, INS, PHG and MB (Bonne et al., 2005; Sullivan et al., 2009) . Since PTSD per definition involves the singular or repeated infliction of an extrinsic (physical) trauma, 5-HT (and, for that matter, also DA and GABA) function may be basically altered in this subtype by interaction with neurotransmitters relevant for the mediation of nociception and acute and/or chronic stress such as substance P (for review, see Nikolaus et al., 2013) , noradrenaline (for review, see Yamamoto et al., 2014) , endocannabinoids (for review, see Hu et al., 2014) and endogenous opiates (for review, see Spetea, 2013) .
Therefore, future investigations are needed, which explicitly address 5-HT (as well as DA and GABA) function in patients with the primary (and preferably exclusive) diagnosis of individual subtypes of AD (OCD, PD, GAD, phobia, PTSD), MDD (melancholic, atypical and catatonic depression, postpartum depression, seasonal affective disorder, etc.), BP (bipolar I disorder, bipolar II disorder, cyclothymia, etc.) or SZ (paranoid, disorganized, catatonic, undifferentiated, residual subtype, etc.) . Correlation of in vivo imaging findings on 5-HT 1 R, 5-HT 2 R, GABA A , D 1 R and/or D 2 R and the occurrence of specific symptoms, then, would be the next step in unraveling the neurochemical mechanisms underlying behavioral manifestations of anxiety, compulsive behavior, delusion, hallucination, anhedonia or mania.
